385ECC71-2BF4-4E14-B2CC-8423E79BDEBE
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.49277266754270693
- age_years
- 60
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.637
- INTERFERON_GAMMA_RESPONSE+0.547
- NOTCH_SIGNALING+0.529
- PROTEIN_SECRETION+0.434
- UV_RESPONSE_DN+0.392
- TGF_BETA_SIGNALING+0.391
- IL6_JAK_STAT3_SIGNALING+0.376
- TNFA_SIGNALING_VIA_NFKB+0.375
- IL2_STAT5_SIGNALING+0.360
- APOPTOSIS+0.342
Top 10 suppressed
- SPERMATOGENESIS-0.366
- KRAS_SIGNALING_DN-0.315
- PANCREAS_BETA_CELLS-0.310
- MYOGENESIS-0.194
- HEDGEHOG_SIGNALING-0.010
- APICAL_JUNCTION-0.003
- ESTROGEN_RESPONSE_LATE+0.021
- APICAL_SURFACE+0.022
- P53_PATHWAY+0.048
- GLYCOLYSIS+0.060
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | B583566B-A014-417A-A973-41204DC35ECF | — | — | 0.938 |
| 2 | 928D2F99-A86B-47CA-A961-A8CAE7B44E78 | — | — | 0.936 |
| 3 | BA28EC2F-5186-4DED-8814-5F0464AB8B87 | — | — | 0.934 |
| 4 | 738B9C39-A73F-4BD5-A8D4-3F75B9E14569 | — | — | 0.932 |
| 5 | 6292335B-7CBB-45BE-AA2A-B39FFDA8768D | — | — | 0.931 |
| 6 | E5FB107A-9555-419F-84BF-2A59873104B9 | — | — | 0.923 |
| 7 | SRR934807 | — | — | 0.922 |
| 8 | 4942E435-61E6-4A43-B031-4E08F0B41186 | — | — | 0.918 |
| 9 | SRR934942 | — | — | 0.916 |
| 10 | 8C34CD93-1AC0-4920-9E72-439EED0CF85D | — | — | 0.915 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 44 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.637 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.547 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.529 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.434 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.392 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.391 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.376 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.375 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.360 | Idelalisib | — uncovered |
| APOPTOSIS | 0.342 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.337 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.335 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.296 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.293 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.275 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.273 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.267 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.263 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.253 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.249 | Inavolisib | — uncovered |